- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The CD38 Monoclonal Antibody Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global CD38 Monoclonal Antibody Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Multiple Myeloma accounting for % of the CD38 Monoclonal Antibody Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Daretuzumab segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of CD38 Monoclonal Antibody Drugs include Johnson, Sanofi, Takeda Pharmaceutical Company, CASI Pharmaceutical Company, and Mab Biopharma, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
CD38 Monoclonal Antibody Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Daretuzumab
Isartuximab
Engineered Toxin Body
Market segment by Application can be divided into
Multiple Myeloma
Diffuse Large B Cell Lymphoma
Other
The key market players for global CD38 Monoclonal Antibody Drugs market are listed below:
Johnson
Sanofi
Takeda Pharmaceutical Company
CASI Pharmaceutical Company
Mab Biopharma
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe CD38 Monoclonal Antibody Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of CD38 Monoclonal Antibody Drugs, with price, sales, revenue and global market share of CD38 Monoclonal Antibody Drugs from 2019 to 2022.
Chapter 3, the CD38 Monoclonal Antibody Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the CD38 Monoclonal Antibody Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and CD38 Monoclonal Antibody Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of CD38 Monoclonal Antibody Drugs.
Chapter 13, 14, and 15, to describe CD38 Monoclonal Antibody Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 CD38 Monoclonal Antibody Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global CD38 Monoclonal Antibody Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Daretuzumab
1.2.3 Isartuximab
1.2.4 Engineered Toxin Body
1.3 Market Analysis by Application
1.3.1 Overview: Global CD38 Monoclonal Antibody Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Multiple Myeloma
1.3.3 Diffuse Large B Cell Lymphoma
1.3.4 Other
1.4 Global CD38 Monoclonal Antibody Drugs Market Size & Forecast
1.4.1 Global CD38 Monoclonal Antibody Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global CD38 Monoclonal Antibody Drugs Sales in Volume (2017-2028)
1.4.3 Global CD38 Monoclonal Antibody Drugs Price (2017-2028)
1.5 Global CD38 Monoclonal Antibody Drugs Production Capacity Analysis
1.5.1 Global CD38 Monoclonal Antibody Drugs Total Production Capacity (2017-2028)
1.5.2 Global CD38 Monoclonal Antibody Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 CD38 Monoclonal Antibody Drugs Market Drivers
1.6.2 CD38 Monoclonal Antibody Drugs Market Restraints
1.6.3 CD38 Monoclonal Antibody Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Johnson
2.1.1 Johnson Details
2.1.2 Johnson Major Business
2.1.3 Johnson CD38 Monoclonal Antibody Drugs Product and Services
2.1.4 Johnson CD38 Monoclonal Antibody Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi CD38 Monoclonal Antibody Drugs Product and Services
2.2.4 Sanofi CD38 Monoclonal Antibody Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Takeda Pharmaceutical Company
2.3.1 Takeda Pharmaceutical Company Details
2.3.2 Takeda Pharmaceutical Company Major Business
2.3.3 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product and Services
2.3.4 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 CASI Pharmaceutical Company
2.4.1 CASI Pharmaceutical Company Details
2.4.2 CASI Pharmaceutical Company Major Business
2.4.3 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product and Services
2.4.4 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Mab Biopharma
2.5.1 Mab Biopharma Details
2.5.2 Mab Biopharma Major Business
2.5.3 Mab Biopharma CD38 Monoclonal Antibody Drugs Product and Services
2.5.4 Mab Biopharma CD38 Monoclonal Antibody Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 CD38 Monoclonal Antibody Drugs Breakdown Data by Manufacturer
3.1 Global CD38 Monoclonal Antibody Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global CD38 Monoclonal Antibody Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in CD38 Monoclonal Antibody Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 CD38 Monoclonal Antibody Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 CD38 Monoclonal Antibody Drugs Manufacturer Market Share in 2021
3.5 Global CD38 Monoclonal Antibody Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and CD38 Monoclonal Antibody Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global CD38 Monoclonal Antibody Drugs Market Size by Region
4.1.1 Global CD38 Monoclonal Antibody Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global CD38 Monoclonal Antibody Drugs Revenue by Region (2017-2028)
4.2 North America CD38 Monoclonal Antibody Drugs Revenue (2017-2028)
4.3 Europe CD38 Monoclonal Antibody Drugs Revenue (2017-2028)
4.4 Asia-Pacific CD38 Monoclonal Antibody Drugs Revenue (2017-2028)
4.5 South America CD38 Monoclonal Antibody Drugs Revenue (2017-2028)
4.6 Middle East and Africa CD38 Monoclonal Antibody Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global CD38 Monoclonal Antibody Drugs Sales in Volume by Type (2017-2028)
5.2 Global CD38 Monoclonal Antibody Drugs Revenue by Type (2017-2028)
5.3 Global CD38 Monoclonal Antibody Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global CD38 Monoclonal Antibody Drugs Sales in Volume by Application (2017-2028)
6.2 Global CD38 Monoclonal Antibody Drugs Revenue by Application (2017-2028)
6.3 Global CD38 Monoclonal Antibody Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America CD38 Monoclonal Antibody Drugs Sales by Type (2017-2028)
7.2 North America CD38 Monoclonal Antibody Drugs Sales by Application (2017-2028)
7.3 North America CD38 Monoclonal Antibody Drugs Market Size by Country
7.3.1 North America CD38 Monoclonal Antibody Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America CD38 Monoclonal Antibody Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe CD38 Monoclonal Antibody Drugs Sales by Type (2017-2028)
8.2 Europe CD38 Monoclonal Antibody Drugs Sales by Application (2017-2028)
8.3 Europe CD38 Monoclonal Antibody Drugs Market Size by Country
8.3.1 Europe CD38 Monoclonal Antibody Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe CD38 Monoclonal Antibody Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific CD38 Monoclonal Antibody Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific CD38 Monoclonal Antibody Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific CD38 Monoclonal Antibody Drugs Market Size by Region
9.3.1 Asia-Pacific CD38 Monoclonal Antibody Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific CD38 Monoclonal Antibody Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America CD38 Monoclonal Antibody Drugs Sales by Type (2017-2028)
10.2 South America CD38 Monoclonal Antibody Drugs Sales by Application (2017-2028)
10.3 South America CD38 Monoclonal Antibody Drugs Market Size by Country
10.3.1 South America CD38 Monoclonal Antibody Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America CD38 Monoclonal Antibody Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa CD38 Monoclonal Antibody Drugs Market Size by Country
11.3.1 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of CD38 Monoclonal Antibody Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of CD38 Monoclonal Antibody Drugs
12.3 CD38 Monoclonal Antibody Drugs Production Process
12.4 CD38 Monoclonal Antibody Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 CD38 Monoclonal Antibody Drugs Typical Distributors
13.3 CD38 Monoclonal Antibody Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global CD38 Monoclonal Antibody Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global CD38 Monoclonal Antibody Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Johnson Basic Information, Manufacturing Base and Competitors
Table 4. Johnson Major Business
Table 5. Johnson CD38 Monoclonal Antibody Drugs Product and Services
Table 6. Johnson CD38 Monoclonal Antibody Drugs Sales (KG), Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Sanofi Basic Information, Manufacturing Base and Competitors
Table 8. Sanofi Major Business
Table 9. Sanofi CD38 Monoclonal Antibody Drugs Product and Services
Table 10. Sanofi CD38 Monoclonal Antibody Drugs Sales (KG), Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Takeda Pharmaceutical Company Basic Information, Manufacturing Base and Competitors
Table 12. Takeda Pharmaceutical Company Major Business
Table 13. Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product and Services
Table 14. Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales (KG), Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. CASI Pharmaceutical Company Basic Information, Manufacturing Base and Competitors
Table 16. CASI Pharmaceutical Company Major Business
Table 17. CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product and Services
Table 18. CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales (KG), Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Mab Biopharma Basic Information, Manufacturing Base and Competitors
Table 20. Mab Biopharma Major Business
Table 21. Mab Biopharma CD38 Monoclonal Antibody Drugs Product and Services
Table 22. Mab Biopharma CD38 Monoclonal Antibody Drugs Sales (KG), Price (US$/g), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Global CD38 Monoclonal Antibody Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (KG)
Table 24. Global CD38 Monoclonal Antibody Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 25. Market Position of Manufacturers in CD38 Monoclonal Antibody Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 26. Global CD38 Monoclonal Antibody Drugs Production Capacity by Company, (KG): 2020 VS 2021
Table 27. Head Office and CD38 Monoclonal Antibody Drugs Production Site of Key Manufacturer
Table 28. CD38 Monoclonal Antibody Drugs New Entrant and Capacity Expansion Plans
Table 29. CD38 Monoclonal Antibody Drugs Mergers & Acquisitions in the Past Five Years
Table 30. Global CD38 Monoclonal Antibody Drugs Sales by Region (2017-2022) & (KG)
Table 31. Global CD38 Monoclonal Antibody Drugs Sales by Region (2023-2028) & (KG)
Table 32. Global CD38 Monoclonal Antibody Drugs Revenue by Region (2017-2022) & (USD Million)
Table 33. Global CD38 Monoclonal Antibody Drugs Revenue by Region (2023-2028) & (USD Million)
Table 34. Global CD38 Monoclonal Antibody Drugs Sales by Type (2017-2022) & (KG)
Table 35. Global CD38 Monoclonal Antibody Drugs Sales by Type (2023-2028) & (KG)
Table 36. Global CD38 Monoclonal Antibody Drugs Revenue by Type (2017-2022) & (USD Million)
Table 37. Global CD38 Monoclonal Antibody Drugs Revenue by Type (2023-2028) & (USD Million)
Table 38. Global CD38 Monoclonal Antibody Drugs Price by Type (2017-2022) & (US$/g)
Table 39. Global CD38 Monoclonal Antibody Drugs Price by Type (2023-2028) & (US$/g)
Table 40. Global CD38 Monoclonal Antibody Drugs Sales by Application (2017-2022) & (KG)
Table 41. Global CD38 Monoclonal Antibody Drugs Sales by Application (2023-2028) & (KG)
Table 42. Global CD38 Monoclonal Antibody Drugs Revenue by Application (2017-2022) & (USD Million)
Table 43. Global CD38 Monoclonal Antibody Drugs Revenue by Application (2023-2028) & (USD Million)
Table 44. Global CD38 Monoclonal Antibody Drugs Price by Application (2017-2022) & (US$/g)
Table 45. Global CD38 Monoclonal Antibody Drugs Price by Application (2023-2028) & (US$/g)
Table 46. North America CD38 Monoclonal Antibody Drugs Sales by Country (2017-2022) & (KG)
Table 47. North America CD38 Monoclonal Antibody Drugs Sales by Country (2023-2028) & (KG)
Table 48. North America CD38 Monoclonal Antibody Drugs Revenue by Country (2017-2022) & (USD Million)
Table 49. North America CD38 Monoclonal Antibody Drugs Revenue by Country (2023-2028) & (USD Million)
Table 50. North America CD38 Monoclonal Antibody Drugs Sales by Type (2017-2022) & (KG)
Table 51. North America CD38 Monoclonal Antibody Drugs Sales by Type (2023-2028) & (KG)
Table 52. North America CD38 Monoclonal Antibody Drugs Sales by Application (2017-2022) & (KG)
Table 53. North America CD38 Monoclonal Antibody Drugs Sales by Application (2023-2028) & (KG)
Table 54. Europe CD38 Monoclonal Antibody Drugs Sales by Country (2017-2022) & (KG)
Table 55. Europe CD38 Monoclonal Antibody Drugs Sales by Country (2023-2028) & (KG)
Table 56. Europe CD38 Monoclonal Antibody Drugs Revenue by Country (2017-2022) & (USD Million)
Table 57. Europe CD38 Monoclonal Antibody Drugs Revenue by Country (2023-2028) & (USD Million)
Table 58. Europe CD38 Monoclonal Antibody Drugs Sales by Type (2017-2022) & (KG)
Table 59. Europe CD38 Monoclonal Antibody Drugs Sales by Type (2023-2028) & (KG)
Table 60. Europe CD38 Monoclonal Antibody Drugs Sales by Application (2017-2022) & (KG)
Table 61. Europe CD38 Monoclonal Antibody Drugs Sales by Application (2023-2028) & (KG)
Table 62. Asia-Pacific CD38 Monoclonal Antibody Drugs Sales by Region (2017-2022) & (KG)
Table 63. Asia-Pacific CD38 Monoclonal Antibody Drugs Sales by Region (2023-2028) & (KG)
Table 64. Asia-Pacific CD38 Monoclonal Antibody Drugs Revenue by Region (2017-2022) & (USD Million)
Table 65. Asia-Pacific CD38 Monoclonal Antibody Drugs Revenue by Region (2023-2028) & (USD Million)
Table 66. Asia-Pacific CD38 Monoclonal Antibody Drugs Sales by Type (2017-2022) & (KG)
Table 67. Asia-Pacific CD38 Monoclonal Antibody Drugs Sales by Type (2023-2028) & (KG)
Table 68. Asia-Pacific CD38 Monoclonal Antibody Drugs Sales by Application (2017-2022) & (KG)
Table 69. Asia-Pacific CD38 Monoclonal Antibody Drugs Sales by Application (2023-2028) & (KG)
Table 70. South America CD38 Monoclonal Antibody Drugs Sales by Country (2017-2022) & (KG)
Table 71. South America CD38 Monoclonal Antibody Drugs Sales by Country (2023-2028) & (KG)
Table 72. South America CD38 Monoclonal Antibody Drugs Revenue by Country (2017-2022) & (USD Million)
Table 73. South America CD38 Monoclonal Antibody Drugs Revenue by Country (2023-2028) & (USD Million)
Table 74. South America CD38 Monoclonal Antibody Drugs Sales by Type (2017-2022) & (KG)
Table 75. South America CD38 Monoclonal Antibody Drugs Sales by Type (2023-2028) & (KG)
Table 76. South America CD38 Monoclonal Antibody Drugs Sales by Application (2017-2022) & (KG)
Table 77. South America CD38 Monoclonal Antibody Drugs Sales by Application (2023-2028) & (KG)
Table 78. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Region (2017-2022) & (KG)
Table 79. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Region (2023-2028) & (KG)
Table 80. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue by Region (2017-2022) & (USD Million)
Table 81. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue by Region (2023-2028) & (USD Million)
Table 82. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Type (2017-2022) & (KG)
Table 83. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Type (2023-2028) & (KG)
Table 84. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Application (2017-2022) & (KG)
Table 85. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Application (2023-2028) & (KG)
Table 86. CD38 Monoclonal Antibody Drugs Raw Material
Table 87. Key Manufacturers of CD38 Monoclonal Antibody Drugs Raw Materials
Table 88. Direct Channel Pros & Cons
Table 89. Indirect Channel Pros & Cons
Table 90. CD38 Monoclonal Antibody Drugs Typical Distributors
Table 91. CD38 Monoclonal Antibody Drugs Typical Customers
List of Figures
Figure 1. CD38 Monoclonal Antibody Drugs Picture
Figure 2. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Type in 2021
Figure 3. Daretuzumab
Figure 4. Isartuximab
Figure 5. Engineered Toxin Body
Figure 6. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Application in 2021
Figure 7. Multiple Myeloma
Figure 8. Diffuse Large B Cell Lymphoma
Figure 9. Other
Figure 10. Global CD38 Monoclonal Antibody Drugs Revenue, (USD Million) & (KG): 2017 & 2021 & 2028
Figure 11. Global CD38 Monoclonal Antibody Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global CD38 Monoclonal Antibody Drugs Sales (2017-2028) & (KG)
Figure 13. Global CD38 Monoclonal Antibody Drugs Price (2017-2028) & (US$/g)
Figure 14. Global CD38 Monoclonal Antibody Drugs Production Capacity (2017-2028) & (KG)
Figure 15. Global CD38 Monoclonal Antibody Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. CD38 Monoclonal Antibody Drugs Market Drivers
Figure 17. CD38 Monoclonal Antibody Drugs Market Restraints
Figure 18. CD38 Monoclonal Antibody Drugs Market Trends
Figure 19. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Manufacturer in 2021
Figure 20. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Manufacturer in 2021
Figure 21. CD38 Monoclonal Antibody Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 CD38 Monoclonal Antibody Drugs Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 CD38 Monoclonal Antibody Drugs Manufacturer (Revenue) Market Share in 2021
Figure 24. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Region (2017-2028)
Figure 25. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Region (2017-2028)
Figure 26. North America CD38 Monoclonal Antibody Drugs Revenue (2017-2028) & (USD Million)
Figure 27. Europe CD38 Monoclonal Antibody Drugs Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific CD38 Monoclonal Antibody Drugs Revenue (2017-2028) & (USD Million)
Figure 29. South America CD38 Monoclonal Antibody Drugs Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2017-2028)
Figure 32. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Type (2017-2028)
Figure 33. Global CD38 Monoclonal Antibody Drugs Price by Type (2017-2028) & (US$/g)
Figure 34. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2017-2028)
Figure 35. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Application (2017-2028)
Figure 36. Global CD38 Monoclonal Antibody Drugs Price by Application (2017-2028) & (US$/g)
Figure 37. North America CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2017-2028)
Figure 38. North America CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2017-2028)
Figure 39. North America CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2017-2028)
Figure 40. North America CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2017-2028)
Figure 41. United States CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2017-2028)
Figure 45. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2017-2028)
Figure 46. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2017-2028)
Figure 47. Europe CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2017-2028)
Figure 48. Germany CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific CD38 Monoclonal Antibody Drugs Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific CD38 Monoclonal Antibody Drugs Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific CD38 Monoclonal Antibody Drugs Revenue Market Share by Region (2017-2028)
Figure 57. China CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2017-2028)
Figure 64. South America CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2017-2028)
Figure 65. South America CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2017-2028)
Figure 66. South America CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2017-2028)
Figure 67. Brazil CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2017-2028)
Figure 71. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue Market Share by Region (2017-2028)
Figure 73. Turkey CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa CD38 Monoclonal Antibody Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of CD38 Monoclonal Antibody Drugs in 2021
Figure 78. Manufacturing Process Analysis of CD38 Monoclonal Antibody Drugs
Figure 79. CD38 Monoclonal Antibody Drugs Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
